Literatura académica sobre el tema "Minimal pharmacophores"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Minimal pharmacophores".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Minimal pharmacophores"
Mortier, Jérémie, Pratik Dhakal y Andrea Volkamer. "Truly Target-Focused Pharmacophore Modeling: A Novel Tool for Mapping Intermolecular Surfaces". Molecules 23, n.º 8 (6 de agosto de 2018): 1959. http://dx.doi.org/10.3390/molecules23081959.
Texto completoPetrikaite, Vilma, Eduardas Tarasevišius y Alvydas Pavilonis. "New ethacridine derivatives as the potential antifungal and antibacterial preparations". Medicina 43, n.º 8 (11 de agosto de 2007): 657. http://dx.doi.org/10.3390/medicina43080084.
Texto completoSpasov, Alexander, Irina Ovchinnikova, Olga Fedorova, Yulia Titova, Denis Babkov, Vadim Kosolapov, Alexander Borisov et al. "Amino Derivatives of Diaryl Pyrimidines and Azolopyrimidines as Protective Agents against LPS-Induced Acute Lung Injury". Molecules 28, n.º 2 (11 de enero de 2023): 741. http://dx.doi.org/10.3390/molecules28020741.
Texto completoMishra, Pranjali, Muskan Srivastav, Yashveer Gautam, Monal Singh, Neeraj Verma, Deepak S. Kapkoti, Shailendra P. Singh, Anil K. Singh y Devendra P. Rao. "A REVIEW IN CURCUMINOIDS: CHEMISTRY, ANTICANCER ACTIVITY AND FUTURE PROSPECTS". INDIAN DRUGS 61, n.º 05 (28 de mayo de 2024): 7–23. http://dx.doi.org/10.53879/id.61.05.14041.
Texto completoMaatuf, Yossi, Matan Geron y Avi Priel. "The Role of Toxins in the Pursuit for Novel Analgesics". Toxins 11, n.º 2 (23 de febrero de 2019): 131. http://dx.doi.org/10.3390/toxins11020131.
Texto completoWermelinger, Guilherme Freimann, Lucas Rubini, Anna Carolina Carvalho da Fonseca, Gabriel Ouverney, Rafael P. R. F. de Oliveira, Acácio S. de Souza, Luana S. M. Forezi, Gabriel Limaverde-Sousa, Sergio Pinheiro y Bruno Kaufmann Robbs. "A Novel MDM2-Binding Chalcone Induces Apoptosis of Oral Squamous Cell Carcinoma". Biomedicines 11, n.º 6 (14 de junio de 2023): 1711. http://dx.doi.org/10.3390/biomedicines11061711.
Texto completoBourne, Yves, Gerlind Sulzenbacher, Laurent Chabaud, Rómulo Aráoz, Zoran Radić, Sandrine Conrod, Palmer Taylor, Catherine Guillou, Jordi Molgó y Pascale Marchot. "The Cyclic Imine Core Common to the Marine Macrocyclic Toxins Is Sufficient to Dictate Nicotinic Acetylcholine Receptor Antagonism". Marine Drugs 22, n.º 4 (27 de marzo de 2024): 149. http://dx.doi.org/10.3390/md22040149.
Texto completoCaldas Lopes, Eloisi, Shieh Jae-Hung, Srikanth Ambati, Su Tsann-Long, Fabian Correa, Elizabeth Peguero y Malcolm A. S. Moore. "Novel Alkylating Agent, Ureidomustine Exhibit Pre-Clinical Efficacy in B-Cell Lymphoma with Minimal Dose-Limiting Myelotoxicity". Blood 126, n.º 23 (3 de diciembre de 2015): 1556. http://dx.doi.org/10.1182/blood.v126.23.1556.1556.
Texto completoVawhal, Pallavi Kishor, Shailaja B. Jadhav, Sumit Kaushik, Kahnu Charan Panigrahi, Chandan Nayak, Humaira Urmee, Sharuk L. Khan et al. "Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay". Molecules 28, n.º 3 (19 de enero de 2023): 1004. http://dx.doi.org/10.3390/molecules28031004.
Texto completoRobertson, Gregory T., Eric J. Bonventre, Timothy B. Doyle, Qun Du, Leonard Duncan, Timothy W. Morris, Eric D. Roche, Dalai Yan y A. Simon Lynch. "In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci". Antimicrobial Agents and Chemotherapy 52, n.º 7 (julio de 2008): 2324–34. http://dx.doi.org/10.1128/aac.01651-07.
Texto completoTesis sobre el tema "Minimal pharmacophores"
Su, Li. "Generation of analogues of the anti-tumor polyketide stambomycins by genetic engineering and allied approaches". Electronic Thesis or Diss., Université de Lorraine, 2021. http://www.theses.fr/2021LORR0081.
Texto completoThe polyketide secondary metabolites of bacteria are a rich source of bioactive agents, with notable applications in anti-infective and anti-cancer therapy. However, their structures often need to be optimized in order to tailor their therapeutic and biophysical properties. The 51-membered macrolide stambomycins, among the largest of known polyketides, were recently discovered by genome mining in Streptomyces ambofaciens ATCC23877, and notably exhibit promising anti-cancer activity. The family encompasses six members which differ from each other in the alkyl functionality at C-26, due to the alternative choice of extender units by an exceptional acyl transferase domain (AT12) of the modular polyketide synthase (PKS) responsible for synthesizing the stambomycin core. Given their enormous size of the stambomycins and the intrinsic promiscuity of AT12, there is substantial interest in accessing ring-contracted and C-26 substituted derivatives of this compounds which might retain the bioactivity of the parental structures, or exhibit improved or even new properties. In this work, we have leveraged our current understanding of modular PKS systems to internally contract the stambomycin assembly line, leading to the successful generation, albeit at low yield, of target smaller derivatives (37-membered ‘mini-stambomycins’). By careful analysis, we could identify multiple factors contributing to the low titers, information which should inform future engineering strategies. Furthermore, using a mutasynthesis strategy, we were able to exploit the broad specificity of the AT12 domain to create 6 novel C-26 substituted stambomycin analogues. Finally, we unexpectedly identified three series of novel desferrioxamine siderophores produced by S. ambofaciens. As a number of key metabolites generated in this work have potential interest for therapeutic applications, they will be targeted for purification, structural characterization and biological evaluation
Capítulos de libros sobre el tema "Minimal pharmacophores"
Rijkers, Dirk T. S., Jack A. J. den Hartog y Rob M. J. Liskamp. "Structure-Activity Studies on the Corticotropin Releasing Factor Antagonist Astressin, Minimal Sequence Necessary for Antagonistic Activity: Implications for a New Pharmacophoric Model". En Peptides: The Wave of the Future, 727–28. Dordrecht: Springer Netherlands, 2001. http://dx.doi.org/10.1007/978-94-010-0464-0_339.
Texto completo